L-732138 NEW
| Price | $31 | $44 | $72 |
| Package | 1mg | 2mg | 5mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-17 |
Product Details
| Product Name: L-732138 | CAS No.: 148451-96-1 |
| Purity: 99.77% | Supply Ability: 10g |
| Release date: 2024/11/17 |
Product Introduction
Bioactivity
| 名稱 | L-732138 |
| 描述 | L-732138 is a potent and competitive antagonist of neurokinin-1 (NK-1) receptor(IC50 : 2.3 nM) |
| 細(xì)胞實(shí)驗(yàn) | Cell Line:COLO 858, MEL HO and COLO 679 cells. Concentration:0 μM, 20 μM, 40 μM, 60 μM, 80 μM, 100 μM. Incubation Time:First doubling time[1]. |
| 動(dòng)物實(shí)驗(yàn) | Animal Model:Male Dunkin-Hartley guinea-pigs (350-500 g) injected with lipopolysaccharide (LPS)[3].Dosage:10-4 mol/kg ,10-3 mol/kg and 10-2 mol/kg. Administration:Intravenous injection; for 15 minutes[2] |
| 體外活性 | L-732,138 against three human melanoma cell lines (COLO 858, MEL HO, COLO 679).?L-732,138 elicits cell growth inhibition in a concentration dependent manner in the melanoma cells studied.?Moreover, L-732,138 blocks SP mitogen stimulation.?The specific antitumor action of L-732,138 occurred through the NK-1 receptor and melanoma cell death was by apoptosis[1]. |
| 體內(nèi)活性 | L-732138?Abolished the vagally-induced plasma leakage in tracheobronchial tissues, and dose-dependently inhibited the LPS enhanced vagally-induced plasma exudation in traceobronchial tissues[2]. |
| 存儲(chǔ)條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| 溶解度 | DMSO : 4.72 mg/mL (10 mM) |
| 關(guān)鍵字 | cytotoxicity | vagally-induced | NK receptor | Neurokinin Receptor | Inhibitor | ntravenously | lipopolysaccharide | plasma | Tachykinin receptor | stimulation | L 732138 | mitogen | peralgesia | inhibit | L-732138 | Antitumorhy | L732138 | apoptotic |
| 相關(guān)產(chǎn)品 | Lanepitant 2HCl | Rolapitant | Ezlopitant | (R)-CJ 11974 | N-Acetyl-L-tryptophan | Netupitant | Aprepitant | Vofopitant dihydrochloride | Befetupitant | Vofopitant | Fosaprepitant dimeglumine | Maropitant |
| 相關(guān)庫(kù) | 經(jīng)典已知活性庫(kù) | 疼痛相關(guān)化合物庫(kù) | 神經(jīng)信號(hào)分子庫(kù) | 膜蛋白靶向化合物庫(kù) | 抑制劑庫(kù) | NO PAINS 化合物庫(kù) | 已知活性化合物庫(kù) | GPCR靶點(diǎn)分子庫(kù) | 抗癌化合物庫(kù) | 抗癌活性化合物庫(kù) |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $45.00/1kg |
VIP1Y
|
Hebei Zhuanglai Chemical Trading Co Ltd
|
2024-12-11 | |
| $54.00/100KG |
VIP4Y
|
Baoji Guokang Bio-Technology Co., Ltd.
|
2021-06-09 | |
| $0.00/1kg |
VIP2Y
|
Sichuan HongRi Pharma-Tech Co.,Ltd
|
2023-09-15 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY